FBIOP News and Press, Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock From 01/10/24

2024-01-10 13:53:59 ET More on Fortress Biotech, Inc. 9.375% CUM PFD A Historical earnings data for Fortress Biotech, Inc. 9.375% CUM PFD A Dividend scorecard for Fortress Biotech, Inc. 9.375% CUM PFD A Financial information for Fortress Biotech, Inc. 9.375% CUM PFD ...

2023-12-06 23:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-07-12 12:30:06 ET Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 ( NASDAQ: FBIOP ) had declared $0.1953/share monthly dividend , in line with previous. Payable July 31; for shareholders of record July 14; ex-div July 13. See FBIOP Dividend Scoreca...

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive Officer Ernie De Paolantonio - Chief Financial Officer Ramsey Allo...

Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 ( NASDAQ: FBIOP ) declares $0.1953/share monthly dividend, Forward yield 12.11% Payable Oct. 31; for shareholders of record Oct. 15; ex-div Oct. 14. Payable Nov. 31; for shareholders of record Nov. 15; e...

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeu...

Journey Medical Corporation (FBIO) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel ...

The market has shown strong support for Alexion YTD, where shareholders have enjoyed +64.28% since the selloff in March. Strong revenue growth on healthy margins paints the picture for periods to come, with equally as satisfying FCF positioning and capital structure. New level of ...

Myovant reports additional data from uterine fibroids study. Fortress Biotech reports start of AL Amyloidosis Phase 3 studies. Avita begins enrolment for vitiligo repigmentation pivotal study. For further details see: Myovant Reports Data, And Other News: The Good, Bad A...

The following slide deck was published by Fortress Biotech, Inc. in conjunction with this Read more ...